These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38383218)

  • 1. AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials.
    Muczynski V; Nathwani AC
    Thromb Res; 2024 Apr; 236():242-249. PubMed ID: 38383218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy in an era of emerging treatment options for hemophilia B.
    Monahan PE
    J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S151-60. PubMed ID: 26149016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy.
    Khan SU; Khan MU; Suleman M; Inam A; Din MAU
    Curr Gene Ther; 2024; 24(4):265-277. PubMed ID: 38284735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia.
    Peyvandi F; Garagiola I
    Haemophilia; 2019 Sep; 25(5):738-746. PubMed ID: 31282050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
    Xue F; Li H; Wu X; Liu W; Zhang F; Tang D; Chen Y; Wang W; Chi Y; Zheng J; Du Z; Jiang W; Zhong C; Wei J; Zhu P; Fu R; Liu X; Chen L; Pei X; Sun J; Cheng T; Yang R; Xiao X; Zhang L
    Lancet Haematol; 2022 Jul; 9(7):e504-e513. PubMed ID: 35598604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fidanacogene Elaparvovec: First Approval.
    Dhillon S
    Drugs; 2024 Apr; 84(4):479-486. PubMed ID: 38472707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemophilia gene therapy: From trailblazer to gamechanger.
    Evens H; Chuah MK; VandenDriessche T
    Haemophilia; 2018 May; 24 Suppl 6():50-59. PubMed ID: 29878653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of haemophilia gene therapy.
    High KH; Nathwani A; Spencer T; Lillicrap D
    Haemophilia; 2014 May; 20 Suppl 4():43-9. PubMed ID: 24762274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemophilia gene therapy-New country initiatives.
    Reiss UM; Zhang L; Ohmori T
    Haemophilia; 2021 Feb; 27 Suppl 3():132-141. PubMed ID: 32638467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WFH State-of-the-art paper 2020: In vivo lentiviral vector gene therapy for haemophilia.
    Cantore A; Naldini L
    Haemophilia; 2021 Feb; 27 Suppl 3(Suppl 3):122-125. PubMed ID: 32537776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemophilia gene therapy: Progress and challenges.
    Lheriteau E; Davidoff AM; Nathwani AC
    Blood Rev; 2015 Sep; 29(5):321-8. PubMed ID: 26049173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.
    Markusic DM; Herzog RW
    J Genet Syndr Gene Ther; 2012 Jan; 1():1-9. PubMed ID: 23565343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
    Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
    Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective.
    Miesbach W; Sawyer EK
    Hum Gene Ther Clin Dev; 2018 Jun; 29(2):80-89. PubMed ID: 29624465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone Transiently Enhances Transgene Expression in the Liver When Administered at Late-Phase Post Long-Term Adeno-Associated Virus Transduction.
    Chai Z; Zhang X; Dobbins AL; Samulski RJ; Merricks EP; Nichols TC; Li C
    Hum Gene Ther; 2022 Feb; 33(3-4):119-130. PubMed ID: 34617445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the art: gene therapy of haemophilia.
    Spencer HT; Riley BE; Doering CB
    Haemophilia; 2016 Jul; 22 Suppl 5():66-71. PubMed ID: 27405679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.